ASCO 2020 VL

Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer: COSMIC-021 - Neeraj Agarwal

Details
Treatment options in metastatic castration-resistant prostate cancer (mCRPC) who have soft-tissue progression after second-generation anti-androgen therapies are limited. Single-agent studies of cabozantinib, a tyrosine kinase inhibitor (TKI) that regulates cell growth, angiogenesis, and immune cell regulation, and the anti-PD-L1 antibody atezolizumab each showed limited efficacy as monotherapy. (...

Personalized Approaches to the Treatment of Prostate Cancer - Kenneth Pienta and James Gulley

Details
Ken Pienta, MD, discusses the role of prostate-specific membrane antigen (PSMA) in facilitating personalized medicine as an imaging agent and selection tool for assigning patients to targeted therapy. He mentions the myriad of trials on PSMA radio-ligand therapeutics that have validated its effect in patients for metastatic prostate cancer. James Gulley, MD, Ph.D., FACS, gives an overview of genom...

Final Overall Survival Analysis of the PROSPER Trial in Nonmetastatic Castration-Resistant Prostate Cancer - Karim Fizazi

Details
Speaking with Alicia Morgans, Karim Fizazi discusses the final overall survival analysis of the PROSPER study in nonmetastatic castration-resistant prostate cancer. Enzalutamide has previously been shown to postpone the time to metastasis or death. Data presented at ASCO 2020 demonstrated that overall survival is significantly improved in patients receiving enzalutamide — median overall survival w...

PROSPER Trial: Significant Improvement in Metastasis-Free Survival (MFS) and Overall Survival (OS) Demonstrated Nonmetastatic Castration-Resistant Prostate Cancer Patients - Fred Saad

Details
Fred Saad joins Alicia Morgans to discuss the updated data from the PROSPER trial of enzalutamide for nonmetastatic castration-resistant prostate cancer. The updated results show that enzalutamide not only improves metastasis-free-survival, as was indicated by the results published in 2018 but also significantly extends overall survival. Biographies: Fred Saad, MD, FRCS, Professor and Chief of Uro...

Blue Light Cystoscopy with Cysview®: Tips and Tricks - Anne Schuckman

Details
Anne Schuckman, MD, MBBS, presents a summary of her plenary session presentation from the AUA 2020 live virtual conference on benefits of Blue Light Cystoscopy (BLC ® ) with Cysview ® , in a conversation with Ashish Kamat, MD. Dr. Schuckman details how Cysview can be used to visualize bladder tumors and highlights benefits arising from this technique including an increased ability to resect the tu...

ARAMIS Trial Demonstrates Significant Improvement in Overall Survival in nmCRPC - Neal Shore

Details
Following a presentation at the ASCO 2020 Annual Meeting, Neal Shore discusses the results of the phase III ARAMIS trial which randomized over 1,500 patients with non-metastatic castration-resistant prostate cancer to 600 mg of darolutamide orally twice daily with ADT, versus a placebo-controlled combination with ADT. The study had a composite endpoint of overall survival and radiographic progress...

Advancements in Treatments for Metastatic Urothelial Carcinoma (mUC) - Petros Grivas

Details
Alicia Morgans, MD, MPH, and Petros Grivas, MD, PhD, discuss the recent updates in the metastatic urothelial carcinoma (mUC) disease space. Together they discuss multiple presentations given during the virtual ASCO 2020 including the IMvigor010 trial. They discuss other adjuvant immunotherapy trials for mUC, as well as new results from IMvigor130 assessing biomarkers. Dr. Morgans and Dr. Grivas al...

JAVELIN Bladder 100: Results of First-line Maintenance Therapy Plus Best Supportive Care Demonstrates Significant Prolonged OS in Advanced Urothelial Cancer - Cora Sternberg

Details
Cora Sternberg, MD, FACP, an investigator on the phase 3 JAVELIN Bladder 100 trial shares the study design, rationale, and key outcomes from the trial. The JAVELIN Bladder 100 trial is a phase 3 randomized study for maintenance avelumab therapy in patients who derived disease response or stabilization from first-line platinum-based chemotherapy for advanced urothelial cancer. In this conversation...

AUA Guidelines Case-Based Panel Discussion: Bladder Cancer (Non-muscle and Muscle Invasive) - Joshua Meeks and Sima Porten

Details
Ashish Kamat, MD, MBBS is joined by Sima Porten, MD, MPH and Joshua Meeks, MD, PhD, panelist in the American Urological Association (AUA) Guidelines Case-Based Panel Discussion on Non-muscle and Muscle Invasive Bladder Cancer AUA 2020 plenary presentation. They provide their perspectives on bladder cancer patient guidelines-based management and the specific management of bladder cancer patients. B...

Changing the Mechanism of Action in The Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC) - Phillip Koo

Details
In conversation with Alicia Morgans, Philip Koo discusses data from a phase II trial that randomized patients to receive radium-223 and sipuleucel-T or sipuleucel-T alone. Dr. Koo explains that patients who received the combination saw a better PSA response, providing evidence for the continued exploration of the combination of radiation and immunotherapy. Biographies: Phillip J. Koo, MD , FACS Di...
email news signup